These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37901236)

  • 1. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.
    Zhu J; Chen Q; Zeng L; Gao H; Wu T; He Y; Xu J; Pang J; Peng J; Deng Y; Han Y; Yi W
    Front Immunol; 2023; 14():1236806. PubMed ID: 37901236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
    Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
    BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer multi-omics analysis of PTBP1 reveals it as an inflammatory, progressive and prognostic marker in glioma.
    Ye Z; Zhong Y; Zhang Z
    Sci Rep; 2024 Jun; 14(1):14584. PubMed ID: 38918441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
    Wang Y; Liu T; Zhang K; Huang RH; Jiang L
    Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
    Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
    J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Origin recognition complex 6 overexpression promotes growth of glioma cells.
    Yang WL; Zhang WF; Wang Y; Lou Y; Cai Y; Zhu J
    Cell Death Dis; 2024 Jul; 15(7):485. PubMed ID: 38971772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
    Feng R; Cheng D; Chen X; Yang L; Wu H
    Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
    Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
    Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.